When to Give A+AVD for Hodgkin Lymphoma
A+AVD (brentuximab vedotin + doxorubicin + vinblastine + dacarbazine) should be used as first-line therapy for previously untreated stage III or IV classic Hodgkin lymphoma in patients under 60 years of age, particularly when IPS ≥4 or when bleomycin is contraindicated, and is FDA-approved for this indication 1.
FDA-Approved Indications
The FDA has specifically approved brentuximab vedotin combined with AVD for:
- Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma 1
- Pediatric patients ≥2 years with previously untreated high-risk classical Hodgkin lymphoma (combined with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide) 1
Clinical Scenarios for A+AVD Use
Primary Indications (Category 2A per NCCN):
A+AVD is the preferred choice when:
- Patient has no known baseline neuropathy 2
- IPS (International Prognostic Score) ≥4 2
- Bleomycin is contraindicated (e.g., pre-existing lung disease, older age with pulmonary concerns) 2
Advanced Stage Disease (Stage III-IV):
For patients <60 years with stage III-IV disease, A+AVD represents a Category 2B recommendation as a general option, but upgrades to Category 2A in the specific scenarios above 2. The ECHELON-1 trial demonstrated superior modified progression-free survival with A+AVD versus ABVD (82.1% vs 77.2% at 2 years), representing a 4.9 percentage point improvement 3.
Older Adults (>60 years):
In elderly patients with stage I-II unfavorable or stage III-IV disease, brentuximab vedotin lead-in followed by AVD with brentuximab vedotin maintenance is included as a primary treatment option 2. This sequential approach showed 2-year event-free survival of 80% with manageable toxicity in this population 2.
Critical Implementation Details
Dosing and Administration:
- Brentuximab vedotin: 1.2 mg/kg IV over 30 minutes on days 1 and 15 of each 28-day cycle 1
- Administered approximately 1 hour after completion of AVD therapy 1
- Standard course: 6 cycles (12 doses total) 1, 3
Mandatory G-CSF Prophylaxis:
Primary G-CSF prophylaxis from Cycle 1 is strongly recommended based on ECHELON-1 data 1. Without prophylaxis, 96% experienced neutropenia (67% Grade 4) and 21% had febrile neutropenia. With prophylaxis, these rates dropped to 61% neutropenia (27% Grade 4) and 11% febrile neutropenia 1.
Important Caveats and Contraindications
Absolute Contraindication:
Never combine brentuximab vedotin with bleomycin - this combination causes unacceptable pulmonary toxicity (44% pulmonary adverse events in phase 1 trial) 4. This is why the regimen uses AVD, not ABVD.
Key Toxicity Considerations:
- Peripheral neuropathy: Occurs in 67% of patients (vs 43% with ABVD), but 67% of affected patients show resolution or improvement at follow-up 3
- Neutropenia: More common than ABVD (58% vs 45%), necessitating G-CSF prophylaxis 3
- Treatment-related deaths: 7 of 9 deaths in ECHELON-1 A+AVD arm were associated with neutropenia in patients who had NOT received G-CSF 1
When NOT to Use A+AVD:
- Pre-existing significant peripheral neuropathy (relative contraindication) 2
- Patients >60 years as standard first-line - consider sequential BV lead-in/maintenance approach instead 2
- Limited stage favorable disease - not indicated; use standard ABVD or AVD 5
Comparison to Alternatives
The ESMO guidelines note that while ABVD remains standard for advanced-stage disease, A+AVD showed superior tumor control in ECHELON-1 5. However, longer follow-up is required for definitive OS benefit, and the regimen carries increased neuropathy and requires careful neutropenia management 5.
The key advantage: A+AVD eliminates bleomycin-related pulmonary toxicity (Grade ≥3 pulmonary toxicity <1% vs 3% with ABVD) while improving disease control 3.